Back to search

United Kingdom· GB-APID-34967111000001104

Vemlidy 25mg tablets

A tenofovir alafenamide product containing tenofovir alafenamide, registered in United Kingdom by Gilead Sciences Ltd. The same ATC class is registered in 14 of our 19 countries.

ATC J05AF13

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedVemlidy 25mg tabletsATCJ05AF13REGISTER NO.GB-APID-3496711100000…PACKS LISTED2CHECKEDSeptember 13, 2026

Where it is registered

Tenofovir alafenamide is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AF13 (tenofovir alafenamide), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 8 of them publish a price we can compare per daily dose

Tenofovir alafenamide · ATC J05AF13

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tenofovir alafenamide costs, country by country.

Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Tenofovir alafenamide · price per daily dose (25 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$20.29
  • IT Italy$18.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Tenofovir alafenamide
Manufacturer
Gilead Sciences Ltd
Country
United Kingdom (GB)
ATC code
J05AF13
ATC class
Tenofovir alafenamide
Defined daily dose
25 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    05391507145895
  • gtin
    05391507145765

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tenofovir alafenamide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tenofovir alafenamide products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Germany · Tenofoviralafenamid Devatis
  • Iceland · Vemlidy
  • Liechtenstein · Vemlidy
  • Netherlands · Tenofoviralafenamide Devatis
  • Norway · Vemlidy
  • Portugal · Tenofovir Alafenamida Humanis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/87f81a8b-802d-442d-95b9-4e2ec3302a6a
GET /v1/drugs/87f81a8b-802d-442d-95b9-4e2ec3302a6a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "34967111000001104",
  "desc": "Vemlidy 25mg tablets (Gilead Sciences Ltd)",
  "form": "Oral tablet",
  "vpid": "34971911000001104",
  "source": "dmd",
  "vtm_id": "34974411000001109",
  "strength": "25 mg",
  "substance": "Tenofovir alafenamide",
  "ingredient": "Tenofovir alafenamide fumarate",
  "supplier_code": "2572301000001107"
}

See everything about tenofovir alafenamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.